GRAIL Stock Tumbles - National Health Service Galleri Trial To Blame
GRAIL Inc. (NASDAQ:GRAL) shares are down during Monday's premarket session following the release of results from the NHS-Galleri trial, which evaluated the effectiveness of the Galleri test in reducing late-stage cancer diagnoses.
NHS-Galleri Trial Results
The NHS-Galleri trial results showed a favorable trend in reducing Stage IV cancer diagnoses, although the primary endpoint was not met. On Friday, GRAIL stock closed almost 51% lower.
The trial evaluated annual multi-cancer screening with the Galleri test in England's National Health Service (NHS) over three years, involving 142,000 participants aged 50 to 77.
The results indicated a clinically meaningful reduction in Stage IV diagnoses across a group of 12 deadly cancers, with a more than 20% reduction observed in subsequent screening rounds.
The broader market experienced declines on the previous trading day, with the Russell 2000 down 0.72% and the S&P 500 falling 0.50%.
GRAIL's decline occurred while the broader market was under pressure, suggesting that the stock's movement is primarily driven by company-specific news rather than overall market trends.
GRAIL's Technical Indicators Highlight Weakness
The stock is currently trading 47.3% below its 20-day simple moving average (SMA) and 40.5% below its 100-day SMA, indicating significant short-term weakness. Shares have increased by 112.58% over the past 12 months and are currently positioned closer to their 52-week lows than highs.
The RSI is at 50.93, which is considered neutral territory, while the MACD is at 0.2738, below its signal line at 0.5506, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum.
- Key Resistance: $52.50
- Key Support: $20.50
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $100.50. Recent analyst moves include:
- Canaccord Genuity: Buy (Lowers Target to $80.00) (Feb. 20)
- Baird: Outperform (Lowers Target to $82.00) (Feb. 20)
GRAL Price Action: Grail shares were down 2.27% at $49.07 during premarket trading on Monday.
Photo by Wirestock Creators via Shutterstock
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
After the US stock market plummeted, "Wood Sister" Cathie Wood said: The more the market worries, the more optimistic I become, the bull market is not over
As the Nasdaq falls into a correction zone, Cathie Wood ("Sister Wood") stated that the prevailing market anxiety actually makes her more confident in the continuation of the bull market. She attributes this correction to pressures in the bond market and controversies over AI capital expenditures, but emphasizes that the technological revolution is still ongoing. She also revealed that ARK has used the opportunity to increase its holdings in high-conviction positions such as SpaceX, and expects the stock market to perform well through 2027.
After the "Black Week" for tech stocks, Wall Street calls for "bottom fishing"
Morgan Stanley has made it clear that "the next two to three weeks are the time to increase positions." Ed Yardeni characterizes the current downturn as a "correction" rather than the bursting of a bubble. Major Wall Street institutions have an average year-end target for the S&P 500 of 7,973 points. However, most strategists believe that the direction of AI policy remains the largest variable.
CoreWeave writes to Texas governor-elect seeking "data center consultation"
In this open letter, Michael Intrator stated that CoreWeave "strongly supports" Hinojosa's principled position that the growth of data centers must benefit the people of Texas. "We welcome the opportunity to work with your transition team to responsibly advance approved projects and to establish clear and lasting standards for future developments," he said.
Crypto prices
More
